Edwin Asturias
Concepts (477)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Guatemala | 54 | 2025 | 345 | 4.040 |
Why?
| | Vaccines | 9 | 2026 | 389 | 3.650 |
Why?
| | Vaccination | 20 | 2026 | 1423 | 3.090 |
Why?
| | Influenza, Human | 11 | 2026 | 616 | 2.720 |
Why?
| | Microcephaly | 5 | 2024 | 103 | 2.630 |
Why?
| | Zika Virus Infection | 6 | 2024 | 168 | 2.590 |
Why?
| | Advisory Committees | 4 | 2026 | 228 | 2.310 |
Why?
| | Rural Population | 18 | 2026 | 650 | 2.230 |
Why?
| | Poliovirus Vaccine, Inactivated | 6 | 2018 | 27 | 2.060 |
Why?
| | Poliomyelitis | 8 | 2018 | 35 | 1.840 |
Why?
| | Health Policy | 4 | 2026 | 400 | 1.760 |
Why?
| | Poliovirus Vaccine, Oral | 7 | 2018 | 25 | 1.700 |
Why?
| | Infant | 49 | 2026 | 10034 | 1.670 |
Why?
| | Zika Virus | 5 | 2024 | 132 | 1.670 |
Why?
| | Dengue | 6 | 2024 | 89 | 1.490 |
Why?
| | Virus Shedding | 10 | 2026 | 48 | 1.450 |
Why?
| | Child Development | 5 | 2025 | 484 | 1.430 |
Why?
| | Policy Making | 4 | 2026 | 82 | 1.400 |
Why?
| | Viral Vaccines | 4 | 2025 | 107 | 1.340 |
Why?
| | Streptococcus pneumoniae | 5 | 2025 | 177 | 1.190 |
Why?
| | Community-Acquired Infections | 4 | 2026 | 174 | 1.150 |
Why?
| | Pneumonia, Pneumococcal | 3 | 2025 | 47 | 1.130 |
Why?
| | Caliciviridae Infections | 2 | 2018 | 18 | 1.070 |
Why?
| | Norovirus | 2 | 2018 | 22 | 1.060 |
Why?
| | Poliovirus | 6 | 2018 | 73 | 1.040 |
Why?
| | Child, Preschool | 34 | 2026 | 11787 | 1.030 |
Why?
| | Gastroenteritis | 2 | 2017 | 63 | 1.000 |
Why?
| | Haemophilus Vaccines | 5 | 2016 | 29 | 1.000 |
Why?
| | Reminder Systems | 2 | 2019 | 141 | 0.980 |
Why?
| | Dengue Virus | 6 | 2024 | 58 | 0.950 |
Why?
| | Hepatitis B Vaccines | 5 | 2026 | 43 | 0.930 |
Why?
| | Humans | 112 | 2026 | 144759 | 0.910 |
Why?
| | Growth Disorders | 2 | 2023 | 86 | 0.900 |
Why?
| | Text Messaging | 2 | 2019 | 182 | 0.890 |
Why?
| | Antigens, Bacterial | 1 | 2025 | 125 | 0.860 |
Why?
| | Health Knowledge, Attitudes, Practice | 5 | 2023 | 1414 | 0.860 |
Why?
| | Fever | 2 | 2017 | 311 | 0.850 |
Why?
| | Family Characteristics | 8 | 2026 | 197 | 0.850 |
Why?
| | Public Health | 4 | 2026 | 566 | 0.830 |
Why?
| | Immunization Schedule | 5 | 2017 | 187 | 0.830 |
Why?
| | Streptococcal Vaccines | 1 | 2023 | 7 | 0.810 |
Why?
| | Immunization | 4 | 2023 | 374 | 0.800 |
Why?
| | Pregnancy Complications, Infectious | 3 | 2026 | 428 | 0.790 |
Why?
| | Child | 32 | 2026 | 22633 | 0.780 |
Why?
| | Meningitis, Meningococcal | 1 | 2022 | 6 | 0.760 |
Why?
| | Neisseria meningitidis | 1 | 2022 | 23 | 0.760 |
Why?
| | Meningococcal Infections | 1 | 2022 | 26 | 0.750 |
Why?
| | Prospective Studies | 20 | 2026 | 7990 | 0.750 |
Why?
| | Cell Phone | 3 | 2019 | 82 | 0.750 |
Why?
| | Meningococcal Vaccines | 1 | 2022 | 58 | 0.730 |
Why?
| | Infant, Newborn | 19 | 2026 | 6429 | 0.710 |
Why?
| | Female | 67 | 2026 | 78271 | 0.700 |
Why?
| | Neurodevelopmental Disorders | 1 | 2024 | 227 | 0.680 |
Why?
| | Streptococcal Infections | 1 | 2023 | 168 | 0.670 |
Why?
| | Serogroup | 5 | 2025 | 44 | 0.650 |
Why?
| | Virus Diseases | 1 | 2022 | 216 | 0.630 |
Why?
| | Antibodies, Neutralizing | 4 | 2017 | 340 | 0.630 |
Why?
| | Endpoint Determination | 1 | 2020 | 83 | 0.630 |
Why?
| | Product Surveillance, Postmarketing | 2 | 2025 | 72 | 0.610 |
Why?
| | Rural Health Services | 2 | 2019 | 141 | 0.610 |
Why?
| | Diarrhea | 5 | 2023 | 192 | 0.600 |
Why?
| | Adverse Drug Reaction Reporting Systems | 2 | 2025 | 81 | 0.600 |
Why?
| | Diphtheria-Tetanus-Pertussis Vaccine | 3 | 2016 | 28 | 0.600 |
Why?
| | Immunity, Humoral | 3 | 2017 | 120 | 0.600 |
Why?
| | Influenza Vaccines | 3 | 2021 | 529 | 0.600 |
Why?
| | Male | 54 | 2026 | 72315 | 0.580 |
Why?
| | Contraception | 4 | 2022 | 169 | 0.580 |
Why?
| | Adolescent Health | 1 | 2019 | 37 | 0.570 |
Why?
| | Hospitalization | 9 | 2026 | 2433 | 0.570 |
Why?
| | Arbovirus Infections | 1 | 2018 | 20 | 0.560 |
Why?
| | Immunity, Mucosal | 2 | 2016 | 98 | 0.560 |
Why?
| | Sentinel Surveillance | 2 | 2017 | 46 | 0.560 |
Why?
| | Community Health Services | 2 | 2019 | 233 | 0.550 |
Why?
| | Haemophilus influenzae type b | 2 | 2014 | 12 | 0.550 |
Why?
| | Patient Acceptance of Health Care | 3 | 2020 | 885 | 0.530 |
Why?
| | Pleural Effusion | 3 | 2026 | 60 | 0.530 |
Why?
| | Carrier State | 3 | 2014 | 79 | 0.530 |
Why?
| | Urban Health Services | 1 | 2017 | 70 | 0.520 |
Why?
| | Immunogenicity, Vaccine | 1 | 2017 | 36 | 0.510 |
Why?
| | Multiplex Polymerase Chain Reaction | 3 | 2025 | 53 | 0.500 |
Why?
| | Consumer Product Safety | 1 | 2016 | 32 | 0.490 |
Why?
| | Community Health Planning | 1 | 2016 | 41 | 0.480 |
Why?
| | Public-Private Sector Partnerships | 1 | 2016 | 44 | 0.470 |
Why?
| | Neonatal Screening | 1 | 2017 | 178 | 0.470 |
Why?
| | Physician Assistants | 1 | 2017 | 102 | 0.460 |
Why?
| | Pregnancy | 15 | 2026 | 7190 | 0.460 |
Why?
| | Family Planning Services | 3 | 2022 | 94 | 0.460 |
Why?
| | Population Health | 1 | 2016 | 44 | 0.460 |
Why?
| | Schools | 1 | 2019 | 453 | 0.460 |
Why?
| | Adolescent | 26 | 2026 | 22428 | 0.460 |
Why?
| | Anemia, Hemolytic | 1 | 2015 | 16 | 0.460 |
Why?
| | Population Surveillance | 2 | 2025 | 485 | 0.450 |
Why?
| | Latin America | 5 | 2018 | 94 | 0.450 |
Why?
| | Immunization Programs | 4 | 2026 | 194 | 0.450 |
Why?
| | Parents | 3 | 2023 | 1403 | 0.450 |
Why?
| | Post-Exposure Prophylaxis | 1 | 2014 | 13 | 0.440 |
Why?
| | Mobile Applications | 1 | 2017 | 196 | 0.430 |
Why?
| | Castleman Disease | 1 | 2014 | 16 | 0.430 |
Why?
| | Herpes Zoster | 2 | 2015 | 315 | 0.430 |
Why?
| | Sexual Behavior | 1 | 2019 | 491 | 0.430 |
Why?
| | Exanthema | 1 | 2015 | 84 | 0.430 |
Why?
| | Young Adult | 21 | 2026 | 14105 | 0.420 |
Why?
| | Haemophilus Infections | 1 | 2014 | 45 | 0.420 |
Why?
| | Brain Diseases | 1 | 2015 | 152 | 0.410 |
Why?
| | Needs Assessment | 2 | 2016 | 404 | 0.410 |
Why?
| | Bacterial Capsules | 2 | 2014 | 33 | 0.400 |
Why?
| | Adolescent Behavior | 1 | 2019 | 501 | 0.400 |
Why?
| | Calcitonin | 1 | 2013 | 27 | 0.400 |
Why?
| | Influenza A Virus, H3N2 Subtype | 2 | 2026 | 50 | 0.400 |
Why?
| | Adult | 35 | 2026 | 40449 | 0.400 |
Why?
| | Receptors, Interleukin-6 | 1 | 2013 | 47 | 0.400 |
Why?
| | Health Behavior | 1 | 2019 | 785 | 0.380 |
Why?
| | Global Health | 1 | 2016 | 401 | 0.380 |
Why?
| | Antibodies, Bacterial | 2 | 2014 | 148 | 0.380 |
Why?
| | Protein Precursors | 1 | 2013 | 137 | 0.380 |
Why?
| | Bacterial Infections | 2 | 2013 | 246 | 0.370 |
Why?
| | Caregivers | 1 | 2021 | 1049 | 0.370 |
Why?
| | Polymerase Chain Reaction | 2 | 2026 | 1054 | 0.360 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 3 | 2025 | 257 | 0.360 |
Why?
| | Feces | 8 | 2018 | 513 | 0.350 |
Why?
| | Intestines | 4 | 2018 | 358 | 0.350 |
Why?
| | Chikungunya Fever | 2 | 2025 | 84 | 0.340 |
Why?
| | Anti-Bacterial Agents | 5 | 2026 | 1907 | 0.340 |
Why?
| | Diet | 1 | 2019 | 1273 | 0.340 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2014 | 985 | 0.330 |
Why?
| | Contraceptive Agents | 2 | 2021 | 65 | 0.320 |
Why?
| | Antigens, Viral | 2 | 2024 | 182 | 0.320 |
Why?
| | Intestinal Mucosa | 1 | 2016 | 676 | 0.320 |
Why?
| | Urban Population | 4 | 2026 | 491 | 0.310 |
Why?
| | Saccharum | 3 | 2020 | 77 | 0.310 |
Why?
| | Hepatitis B Antibodies | 1 | 2009 | 6 | 0.300 |
Why?
| | United States | 13 | 2026 | 15966 | 0.300 |
Why?
| | Surveys and Questionnaires | 5 | 2021 | 6048 | 0.290 |
Why?
| | Cross-Sectional Studies | 7 | 2026 | 5868 | 0.290 |
Why?
| | Nasopharynx | 2 | 2025 | 73 | 0.280 |
Why?
| | Immunosuppressive Agents | 1 | 2013 | 846 | 0.280 |
Why?
| | Biomarkers | 2 | 2025 | 4271 | 0.280 |
Why?
| | Dengue Vaccines | 2 | 2018 | 11 | 0.280 |
Why?
| | Agriculture | 2 | 2020 | 104 | 0.280 |
Why?
| | Delivery, Obstetric | 2 | 2019 | 160 | 0.280 |
Why?
| | Influenza A virus | 2 | 2026 | 113 | 0.270 |
Why?
| | Antibodies, Viral | 7 | 2022 | 672 | 0.270 |
Why?
| | Malnutrition | 1 | 2009 | 86 | 0.270 |
Why?
| | World Health Organization | 3 | 2017 | 105 | 0.270 |
Why?
| | Cohort Studies | 7 | 2025 | 5960 | 0.270 |
Why?
| | Appointments and Schedules | 2 | 2019 | 97 | 0.260 |
Why?
| | Postpartum Period | 4 | 2026 | 365 | 0.250 |
Why?
| | Emergency Service, Hospital | 3 | 2026 | 2310 | 0.250 |
Why?
| | Primary Health Care | 1 | 2017 | 1733 | 0.250 |
Why?
| | RNA, Viral | 2 | 2021 | 688 | 0.250 |
Why?
| | Seroconversion | 2 | 2017 | 49 | 0.240 |
Why?
| | Acute Disease | 3 | 2019 | 1030 | 0.240 |
Why?
| | Empyema | 1 | 2026 | 8 | 0.240 |
Why?
| | Neonatal Sepsis | 1 | 2026 | 8 | 0.240 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2026 | 33 | 0.230 |
Why?
| | Glomerular Filtration Rate | 2 | 2020 | 760 | 0.220 |
Why?
| | Blood Culture | 1 | 2025 | 25 | 0.220 |
Why?
| | Azithromycin | 1 | 2026 | 104 | 0.220 |
Why?
| | Anthropometry | 2 | 2022 | 200 | 0.220 |
Why?
| | Molecular Diagnostic Techniques | 2 | 2026 | 104 | 0.210 |
Why?
| | Vaccines, Conjugate | 2 | 2022 | 60 | 0.210 |
Why?
| | Viral Load | 2 | 2024 | 526 | 0.210 |
Why?
| | Chikungunya virus | 1 | 2025 | 86 | 0.210 |
Why?
| | Head | 1 | 2025 | 120 | 0.210 |
Why?
| | Meningitis, Haemophilus | 1 | 2003 | 6 | 0.200 |
Why?
| | Bacteremia | 2 | 2025 | 221 | 0.200 |
Why?
| | Sepsis | 3 | 2026 | 640 | 0.200 |
Why?
| | Viruses | 2 | 2023 | 165 | 0.200 |
Why?
| | Culex | 1 | 2023 | 14 | 0.200 |
Why?
| | Ritonavir | 1 | 2024 | 75 | 0.200 |
Why?
| | Antiviral Agents | 3 | 2026 | 767 | 0.200 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2025 | 136 | 0.200 |
Why?
| | Cost of Illness | 1 | 2026 | 321 | 0.200 |
Why?
| | Streptococcus pyogenes | 1 | 2023 | 41 | 0.200 |
Why?
| | Saliva | 1 | 2025 | 249 | 0.200 |
Why?
| | Risk Factors | 11 | 2025 | 10779 | 0.190 |
Why?
| | Hot Temperature | 1 | 2026 | 407 | 0.190 |
Why?
| | Antimicrobial Stewardship | 1 | 2025 | 129 | 0.190 |
Why?
| | Aedes | 1 | 2023 | 65 | 0.190 |
Why?
| | Postnatal Care | 2 | 2021 | 72 | 0.190 |
Why?
| | Aspirin | 1 | 2026 | 399 | 0.190 |
Why?
| | Sequence Analysis, DNA | 1 | 2026 | 824 | 0.190 |
Why?
| | Anti-Infective Agents | 2 | 2020 | 242 | 0.190 |
Why?
| | Vomiting | 1 | 2023 | 130 | 0.190 |
Why?
| | Incidence | 4 | 2022 | 2879 | 0.190 |
Why?
| | Psychometrics | 3 | 2021 | 734 | 0.190 |
Why?
| | Seroepidemiologic Studies | 2 | 2022 | 172 | 0.180 |
Why?
| | Travel | 3 | 2015 | 136 | 0.180 |
Why?
| | Vital Signs | 1 | 2022 | 48 | 0.180 |
Why?
| | Cough | 1 | 2023 | 124 | 0.180 |
Why?
| | Seasons | 2 | 2025 | 556 | 0.180 |
Why?
| | Regression Analysis | 2 | 2022 | 1003 | 0.180 |
Why?
| | Vaccines, Attenuated | 2 | 2025 | 129 | 0.180 |
Why?
| | Propensity Score | 1 | 2024 | 367 | 0.180 |
Why?
| | Ambulatory Care | 2 | 2026 | 600 | 0.180 |
Why?
| | Premature Birth | 1 | 2026 | 380 | 0.180 |
Why?
| | Meningitis, Bacterial | 2 | 2015 | 45 | 0.180 |
Why?
| | Herpesvirus 3, Human | 2 | 2015 | 336 | 0.180 |
Why?
| | Drug Therapy, Combination | 3 | 2016 | 1047 | 0.170 |
Why?
| | Quality Improvement | 5 | 2022 | 1289 | 0.170 |
Why?
| | Escherichia coli Vaccines | 2 | 2013 | 4 | 0.170 |
Why?
| | Vaccines, Combined | 3 | 2024 | 49 | 0.170 |
Why?
| | Sensitivity and Specificity | 5 | 2026 | 1985 | 0.170 |
Why?
| | Attitude | 1 | 2023 | 260 | 0.170 |
Why?
| | Malaria Vaccines | 1 | 2020 | 11 | 0.170 |
Why?
| | Health Promotion | 2 | 2019 | 774 | 0.170 |
Why?
| | Cesarean Section | 2 | 2019 | 224 | 0.170 |
Why?
| | Respiratory Tract Infections | 1 | 2025 | 397 | 0.160 |
Why?
| | Midwifery | 1 | 2022 | 64 | 0.160 |
Why?
| | Immunologic Deficiency Syndromes | 2 | 2015 | 65 | 0.160 |
Why?
| | Yellow fever virus | 1 | 2020 | 4 | 0.160 |
Why?
| | Birth Intervals | 1 | 2020 | 23 | 0.160 |
Why?
| | Outpatients | 1 | 2024 | 442 | 0.160 |
Why?
| | Health Services Accessibility | 2 | 2020 | 1098 | 0.160 |
Why?
| | Yellow Fever | 1 | 2020 | 9 | 0.160 |
Why?
| | Reproducibility of Results | 4 | 2021 | 3409 | 0.160 |
Why?
| | Maternal Health Services | 1 | 2022 | 102 | 0.160 |
Why?
| | Vaccination Refusal | 1 | 2020 | 64 | 0.160 |
Why?
| | Middle Aged | 14 | 2026 | 35875 | 0.160 |
Why?
| | Absenteeism | 1 | 2020 | 53 | 0.160 |
Why?
| | Cesarean Section, Repeat | 1 | 2019 | 11 | 0.160 |
Why?
| | Intensive Care, Neonatal | 1 | 2020 | 42 | 0.160 |
Why?
| | Colorado | 4 | 2026 | 4564 | 0.150 |
Why?
| | Vaginal Birth after Cesarean | 1 | 2019 | 27 | 0.150 |
Why?
| | Agricultural Workers' Diseases | 1 | 2020 | 30 | 0.150 |
Why?
| | Language Tests | 1 | 2019 | 23 | 0.150 |
Why?
| | Drug Discovery | 1 | 2020 | 155 | 0.150 |
Why?
| | Contraception Behavior | 1 | 2020 | 107 | 0.150 |
Why?
| | Bayes Theorem | 3 | 2026 | 433 | 0.150 |
Why?
| | Communication | 1 | 2026 | 965 | 0.150 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2020 | 341 | 0.150 |
Why?
| | Maternal Age | 1 | 2019 | 126 | 0.150 |
Why?
| | Language Development Disorders | 1 | 2019 | 40 | 0.150 |
Why?
| | Motor Skills | 1 | 2020 | 104 | 0.140 |
Why?
| | Arboviruses | 1 | 2018 | 14 | 0.140 |
Why?
| | Thinness | 1 | 2019 | 99 | 0.140 |
Why?
| | Puerto Rico | 1 | 2018 | 58 | 0.140 |
Why?
| | Entamoeba histolytica | 1 | 2018 | 10 | 0.140 |
Why?
| | Clinical Trials as Topic | 1 | 2023 | 1053 | 0.140 |
Why?
| | Farmers | 1 | 2019 | 69 | 0.140 |
Why?
| | Pregnancy in Adolescence | 1 | 2019 | 84 | 0.140 |
Why?
| | Socioeconomic Factors | 2 | 2025 | 1326 | 0.140 |
Why?
| | Heat Stress Disorders | 1 | 2019 | 84 | 0.130 |
Why?
| | Treatment Refusal | 1 | 2018 | 98 | 0.130 |
Why?
| | Vulnerable Populations | 1 | 2019 | 177 | 0.130 |
Why?
| | Mothers | 3 | 2022 | 775 | 0.130 |
Why?
| | Aged, 80 and over | 3 | 2026 | 8265 | 0.130 |
Why?
| | Child Health | 1 | 2019 | 157 | 0.130 |
Why?
| | Educational Status | 1 | 2019 | 467 | 0.130 |
Why?
| | Pneumococcal Infections | 2 | 2016 | 103 | 0.130 |
Why?
| | Diagnostic Tests, Routine | 1 | 2018 | 108 | 0.130 |
Why?
| | Aged | 10 | 2026 | 25913 | 0.130 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2020 | 279 | 0.130 |
Why?
| | Health Surveys | 1 | 2019 | 518 | 0.130 |
Why?
| | Poliovirus Vaccines | 1 | 2016 | 6 | 0.130 |
Why?
| | Central Nervous System Viral Diseases | 1 | 2018 | 78 | 0.120 |
Why?
| | Occupational Health | 2 | 2018 | 209 | 0.120 |
Why?
| | Child Behavior | 1 | 2019 | 236 | 0.120 |
Why?
| | Myelitis | 1 | 2018 | 107 | 0.120 |
Why?
| | Panama | 1 | 2016 | 14 | 0.120 |
Why?
| | Colombia | 1 | 2016 | 42 | 0.120 |
Why?
| | Dominican Republic | 1 | 2016 | 26 | 0.120 |
Why?
| | Neoplasms | 2 | 2016 | 2875 | 0.120 |
Why?
| | Risk-Taking | 1 | 2019 | 328 | 0.120 |
Why?
| | Peru | 1 | 2016 | 62 | 0.120 |
Why?
| | Community Health Nursing | 1 | 2016 | 63 | 0.120 |
Why?
| | Host-Pathogen Interactions | 1 | 2019 | 371 | 0.120 |
Why?
| | Rotavirus Vaccines | 1 | 2016 | 37 | 0.120 |
Why?
| | Sanitation | 1 | 2016 | 55 | 0.120 |
Why?
| | Databases, Factual | 3 | 2019 | 1486 | 0.120 |
Why?
| | HIV Infections | 2 | 2014 | 3154 | 0.120 |
Why?
| | Measles-Mumps-Rubella Vaccine | 1 | 2016 | 47 | 0.120 |
Why?
| | Anemia, Hemolytic, Autoimmune | 1 | 2015 | 14 | 0.120 |
Why?
| | Neuromuscular Diseases | 1 | 2018 | 146 | 0.120 |
Why?
| | Water Supply | 1 | 2016 | 88 | 0.110 |
Why?
| | Chickenpox | 1 | 2016 | 81 | 0.110 |
Why?
| | Analysis of Variance | 1 | 2018 | 1306 | 0.110 |
Why?
| | Learning | 1 | 2020 | 452 | 0.110 |
Why?
| | Health Services Needs and Demand | 1 | 2017 | 280 | 0.110 |
Why?
| | Single-Blind Method | 1 | 2016 | 312 | 0.110 |
Why?
| | Enterovirus Infections | 1 | 2018 | 173 | 0.110 |
Why?
| | Typhoid Fever | 1 | 2015 | 12 | 0.110 |
Why?
| | Data Collection | 1 | 2018 | 633 | 0.110 |
Why?
| | Health Information Systems | 1 | 2015 | 16 | 0.110 |
Why?
| | Occupational Exposure | 1 | 2019 | 354 | 0.110 |
Why?
| | Community Participation | 1 | 2016 | 132 | 0.110 |
Why?
| | Patient Preference | 1 | 2017 | 224 | 0.110 |
Why?
| | Education, Nursing | 1 | 2016 | 93 | 0.110 |
Why?
| | Antibody Affinity | 1 | 2014 | 60 | 0.110 |
Why?
| | Disease Outbreaks | 1 | 2018 | 422 | 0.110 |
Why?
| | Fatal Outcome | 1 | 2015 | 307 | 0.110 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 97 | 0.110 |
Why?
| | Malaria | 1 | 2015 | 73 | 0.100 |
Why?
| | Biomedical Research | 1 | 2020 | 710 | 0.100 |
Why?
| | Cyclophosphamide | 1 | 2014 | 266 | 0.100 |
Why?
| | Vincristine | 1 | 2014 | 140 | 0.100 |
Why?
| | Mucocutaneous Lymph Node Syndrome | 1 | 2014 | 91 | 0.100 |
Why?
| | History, 21st Century | 1 | 2014 | 219 | 0.100 |
Why?
| | Overweight | 1 | 2019 | 609 | 0.100 |
Why?
| | Enterotoxins | 1 | 2013 | 89 | 0.100 |
Why?
| | Severity of Illness Index | 2 | 2020 | 2925 | 0.100 |
Why?
| | Prednisone | 1 | 2014 | 221 | 0.100 |
Why?
| | Universities | 1 | 2016 | 452 | 0.100 |
Why?
| | Rituximab | 1 | 2014 | 209 | 0.100 |
Why?
| | Calcitonin Gene-Related Peptide | 1 | 2013 | 40 | 0.100 |
Why?
| | History, 20th Century | 1 | 2014 | 325 | 0.100 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2020 | 653 | 0.100 |
Why?
| | Bacterial Toxins | 1 | 2013 | 109 | 0.100 |
Why?
| | Case-Control Studies | 1 | 2021 | 3604 | 0.100 |
Why?
| | Developing Countries | 3 | 2026 | 318 | 0.100 |
Why?
| | Students | 1 | 2019 | 663 | 0.100 |
Why?
| | Causality | 1 | 2013 | 126 | 0.100 |
Why?
| | Education, Medical | 1 | 2016 | 274 | 0.090 |
Why?
| | Communicable Diseases | 1 | 2015 | 163 | 0.090 |
Why?
| | Delivery of Health Care | 1 | 2019 | 947 | 0.090 |
Why?
| | Lymphocytes | 1 | 2014 | 382 | 0.090 |
Why?
| | Doxorubicin | 1 | 2014 | 397 | 0.090 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1560 | 0.090 |
Why?
| | Time Factors | 5 | 2026 | 7173 | 0.090 |
Why?
| | Gene Expression Profiling | 1 | 2019 | 1782 | 0.090 |
Why?
| | Escherichia coli Proteins | 1 | 2013 | 206 | 0.090 |
Why?
| | Lymph Nodes | 1 | 2014 | 502 | 0.090 |
Why?
| | Program Evaluation | 1 | 2016 | 948 | 0.090 |
Why?
| | Hypertension | 1 | 2020 | 1263 | 0.080 |
Why?
| | Acute Kidney Injury | 1 | 2019 | 865 | 0.080 |
Why?
| | ROC Curve | 2 | 2026 | 614 | 0.080 |
Why?
| | Interleukin-6 | 1 | 2014 | 780 | 0.080 |
Why?
| | Kidney | 1 | 2018 | 1495 | 0.080 |
Why?
| | Immunization, Secondary | 1 | 2010 | 91 | 0.080 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2011 | 157 | 0.080 |
Why?
| | Decision Support Systems, Clinical | 1 | 2013 | 265 | 0.070 |
Why?
| | Clinical Competence | 1 | 2017 | 1244 | 0.070 |
Why?
| | Escherichia coli | 1 | 2013 | 854 | 0.070 |
Why?
| | Double-Blind Method | 3 | 2026 | 2029 | 0.070 |
Why?
| | Physicians | 1 | 2017 | 939 | 0.070 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2007 | 42 | 0.070 |
Why?
| | Creatinine | 2 | 2020 | 506 | 0.070 |
Why?
| | Penicillins | 1 | 2007 | 61 | 0.070 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2007 | 81 | 0.060 |
Why?
| | Glucagon-Like Peptide 2 | 1 | 2025 | 7 | 0.060 |
Why?
| | Kenya | 1 | 2026 | 129 | 0.060 |
Why?
| | Contact Tracing | 1 | 2025 | 26 | 0.060 |
Why?
| | Drug Administration Schedule | 1 | 2007 | 779 | 0.060 |
Why?
| | Hepatitis B | 1 | 2026 | 66 | 0.060 |
Why?
| | Influenza B virus | 1 | 2025 | 47 | 0.060 |
Why?
| | Prevalence | 2 | 2025 | 2834 | 0.060 |
Why?
| | Cities | 2 | 2016 | 143 | 0.060 |
Why?
| | Basic Reproduction Number | 1 | 2025 | 6 | 0.060 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 1953 | 0.050 |
Why?
| | Neuropsychological Tests | 2 | 2020 | 1134 | 0.050 |
Why?
| | DNA, Bacterial | 1 | 2026 | 342 | 0.050 |
Why?
| | Mexico | 3 | 2013 | 233 | 0.050 |
Why?
| | Respiratory Syncytial Virus, Human | 1 | 2025 | 81 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2730 | 0.050 |
Why?
| | Mosquito Vectors | 1 | 2023 | 28 | 0.050 |
Why?
| | Haemophilus influenzae | 1 | 2003 | 67 | 0.050 |
Why?
| | Chickens | 1 | 2023 | 191 | 0.050 |
Why?
| | Administration, Oral | 1 | 2026 | 847 | 0.050 |
Why?
| | China | 1 | 2024 | 269 | 0.050 |
Why?
| | Treatment Outcome | 4 | 2020 | 11679 | 0.050 |
Why?
| | Cross Reactions | 1 | 2022 | 130 | 0.050 |
Why?
| | Gestational Age | 1 | 2026 | 975 | 0.050 |
Why?
| | Pandemics | 1 | 2011 | 1694 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2019 | 1720 | 0.040 |
Why?
| | Mammals | 1 | 2023 | 293 | 0.040 |
Why?
| | Longitudinal Studies | 2 | 2020 | 2947 | 0.040 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2024 | 248 | 0.040 |
Why?
| | Administration, Cutaneous | 2 | 2013 | 125 | 0.040 |
Why?
| | Hospitals | 2 | 2016 | 730 | 0.040 |
Why?
| | Paraguay | 1 | 2020 | 3 | 0.040 |
Why?
| | Sri Lanka | 1 | 2020 | 7 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2022 | 851 | 0.040 |
Why?
| | Endemic Diseases | 1 | 2020 | 33 | 0.040 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2020 | 34 | 0.040 |
Why?
| | Translations | 1 | 2020 | 18 | 0.040 |
Why?
| | Home Health Nursing | 1 | 2019 | 13 | 0.040 |
Why?
| | Parity | 1 | 2019 | 109 | 0.040 |
Why?
| | Specific Gravity | 1 | 2019 | 11 | 0.040 |
Why?
| | Hospitals, Pediatric | 2 | 2015 | 556 | 0.040 |
Why?
| | Prenatal Care | 1 | 2022 | 307 | 0.040 |
Why?
| | Child Language | 1 | 2019 | 21 | 0.040 |
Why?
| | Translating | 1 | 2019 | 50 | 0.040 |
Why?
| | Rural Health | 1 | 2019 | 87 | 0.040 |
Why?
| | Electrolytes | 1 | 2019 | 55 | 0.040 |
Why?
| | Dehydration | 1 | 2019 | 56 | 0.040 |
Why?
| | Parasites | 1 | 2019 | 44 | 0.040 |
Why?
| | Reproductive Health | 1 | 2019 | 91 | 0.040 |
Why?
| | Work Capacity Evaluation | 1 | 2018 | 11 | 0.040 |
Why?
| | Culturally Competent Care | 1 | 2019 | 74 | 0.040 |
Why?
| | Decision Making | 1 | 2026 | 975 | 0.030 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2020 | 193 | 0.030 |
Why?
| | Bacteria | 2 | 2019 | 889 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2019 | 529 | 0.030 |
Why?
| | Education, Medical, Continuing | 1 | 2019 | 132 | 0.030 |
Why?
| | Coinfection | 1 | 2019 | 141 | 0.030 |
Why?
| | Licensure | 1 | 2017 | 16 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2022 | 1095 | 0.030 |
Why?
| | House Calls | 1 | 2019 | 154 | 0.030 |
Why?
| | Chromatography, Affinity | 1 | 2017 | 85 | 0.030 |
Why?
| | Adjuvants, Immunologic | 1 | 2019 | 245 | 0.030 |
Why?
| | Epitope Mapping | 1 | 2017 | 61 | 0.030 |
Why?
| | Choice Behavior | 1 | 2019 | 177 | 0.030 |
Why?
| | Paralysis | 1 | 2018 | 67 | 0.030 |
Why?
| | Francisella | 1 | 1997 | 2 | 0.030 |
Why?
| | Parenteral Nutrition | 1 | 1998 | 105 | 0.030 |
Why?
| | Women's Health | 1 | 2019 | 310 | 0.030 |
Why?
| | Retrospective Studies | 4 | 2020 | 17066 | 0.030 |
Why?
| | Pregnancy Outcome | 1 | 2020 | 476 | 0.030 |
Why?
| | Counseling | 1 | 2020 | 408 | 0.030 |
Why?
| | Granulomatous Disease, Chronic | 1 | 1997 | 48 | 0.030 |
Why?
| | Sequence Alignment | 1 | 2017 | 366 | 0.030 |
Why?
| | Gastrointestinal Tract | 1 | 2019 | 208 | 0.030 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 1997 | 51 | 0.030 |
Why?
| | Enterovirus D, Human | 1 | 2018 | 87 | 0.030 |
Why?
| | Acyclovir | 1 | 2016 | 96 | 0.030 |
Why?
| | Chile | 1 | 2015 | 26 | 0.030 |
Why?
| | Cholestasis | 1 | 1998 | 219 | 0.030 |
Why?
| | IgG Deficiency | 2 | 2006 | 6 | 0.030 |
Why?
| | Age Distribution | 1 | 2016 | 403 | 0.030 |
Why?
| | IgA Deficiency | 2 | 2006 | 5 | 0.030 |
Why?
| | Sex Distribution | 1 | 2016 | 386 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2016 | 423 | 0.030 |
Why?
| | Pneumococcal Vaccines | 1 | 2016 | 130 | 0.030 |
Why?
| | Residence Characteristics | 1 | 2018 | 377 | 0.030 |
Why?
| | Spleen | 1 | 1997 | 508 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2015 | 215 | 0.030 |
Why?
| | Pedigree | 1 | 2015 | 514 | 0.030 |
Why?
| | Computational Biology | 1 | 2019 | 680 | 0.030 |
Why?
| | Blood Pressure | 1 | 2021 | 1769 | 0.030 |
Why?
| | Maternal-Fetal Exchange | 1 | 2014 | 169 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2017 | 2155 | 0.020 |
Why?
| | Europe | 1 | 2013 | 412 | 0.020 |
Why?
| | Transcriptome | 1 | 2019 | 1045 | 0.020 |
Why?
| | Adrenal Cortex Hormones | 1 | 2015 | 478 | 0.020 |
Why?
| | Checklist | 1 | 2013 | 107 | 0.020 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2015 | 549 | 0.020 |
Why?
| | Survival Analysis | 1 | 2015 | 1382 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2015 | 1126 | 0.020 |
Why?
| | Oncology Service, Hospital | 1 | 2011 | 15 | 0.020 |
Why?
| | Oseltamivir | 1 | 2011 | 14 | 0.020 |
Why?
| | Survival Rate | 1 | 2016 | 2089 | 0.020 |
Why?
| | Comorbidity | 1 | 2016 | 1658 | 0.020 |
Why?
| | Smoking | 1 | 2018 | 1472 | 0.020 |
Why?
| | Nuclear Proteins | 1 | 2015 | 748 | 0.020 |
Why?
| | El Salvador | 1 | 2010 | 6 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 1519 | 0.020 |
Why?
| | Drug Delivery Systems | 1 | 2013 | 380 | 0.020 |
Why?
| | Body Mass Index | 1 | 2018 | 2438 | 0.020 |
Why?
| | Animals | 2 | 2023 | 38058 | 0.020 |
Why?
| | Latex Fixation Tests | 1 | 2008 | 4 | 0.020 |
Why?
| | Brain Damage, Chronic | 1 | 2008 | 18 | 0.020 |
Why?
| | Leukocytosis | 1 | 2008 | 32 | 0.020 |
Why?
| | Coma | 1 | 2008 | 37 | 0.020 |
Why?
| | Bacteriological Techniques | 1 | 2008 | 68 | 0.020 |
Why?
| | Cerebrospinal Fluid | 1 | 2008 | 88 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 2015 | 1499 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2015 | 4154 | 0.020 |
Why?
| | Child Day Care Centers | 1 | 2007 | 44 | 0.020 |
Why?
| | Shock | 1 | 2008 | 108 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2016 | 5408 | 0.020 |
Why?
| | Risk Assessment | 1 | 2016 | 3671 | 0.020 |
Why?
| | Ethiopia | 1 | 2006 | 44 | 0.020 |
Why?
| | Pakistan | 1 | 2006 | 78 | 0.020 |
Why?
| | Microbial Sensitivity Tests | 1 | 2007 | 370 | 0.020 |
Why?
| | Postoperative Complications | 1 | 1998 | 2919 | 0.010 |
Why?
| | Algorithms | 1 | 2013 | 1837 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2016 | 2194 | 0.010 |
Why?
| | Common Variable Immunodeficiency | 1 | 2004 | 26 | 0.010 |
Why?
| | Agammaglobulinemia | 1 | 2004 | 36 | 0.010 |
Why?
| | Brazil | 1 | 2004 | 180 | 0.010 |
Why?
| | Confidence Intervals | 1 | 2004 | 333 | 0.010 |
Why?
| | United Kingdom | 1 | 2004 | 338 | 0.010 |
Why?
| | Short Bowel Syndrome | 1 | 1998 | 27 | 0.010 |
Why?
| | Bilirubin | 1 | 1998 | 97 | 0.010 |
Why?
| | Liver Failure | 1 | 1998 | 83 | 0.010 |
Why?
| | Abscess | 1 | 1997 | 75 | 0.010 |
Why?
| | Water Microbiology | 1 | 1997 | 90 | 0.010 |
Why?
|
|
Asturias's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|